

Clinical Trial Protocol

Iranian Registry of Clinical Trials

04 Jun 2026

Comparison of therapeutic effects of Iranian surfactant (Beraksurf) with Cursorf in premature infants with respiratory distress admitted to the neonatal intensive care unit of Hafez and Namazi hospitals in Shiraz in 1400

Protocol summary

Study aim

Determining the therapeutic effects of surfactant made in Iran (Beraksurf) compared to cursorf in treatment of neonates with respiratory syndrome admitted in neonatal intensive care unit in Hafez and Namazi hospital

Design

A randomized clinical trial with parallel two intervention groups (1 and 2), single blinded, randomized, N= 100 patients (each group N= 50) and phase 2. Block randomization will be used for randomization.

Settings and conduct

This research includes preterm neonates, admitted to Hafez or Namazi hospital who need receiving surfactant. Then beraksurf or cursorf is given. Blinding in this research is single-blind and parents do not know their neonate is in which group.

Participants/Inclusion and exclusion criteria

Inclusion criteria: gestational age less than 37 weeks, the clinical or radiologic signs of respiratory distress syndrome, need Fio2 more than 30% in the first 6hour of life to keep saturation 92-95%. Exclusion criteria: congenital disease or anomalies, receiving two types of surfactant, neonates who need an operation, neonates with congenital heart or lung disease, or abdominal pathology.

Intervention groups

The first group consists of neonates receiving Beraksurf and the second group of neonates receiving Cursorf due to respiratory distress syndrome.

Main outcome variables

Need a ventilator; O2 saturation rate; Sepsis

General information

Reason for update

Acronym

IRCT registration information

IRCT registration number: **IRCT20120126008827N3**

Registration date: **2022-01-09, 1400/10/19**

Registration timing: **registered_while_recruiting**

Last update: **2022-01-09, 1400/10/19**

Update count: **0**

Registration date

2022-01-09, 1400/10/19

Registrant information

Name

Khadijeh Sadat Najib

Name of organization / entity

Shiraz University of Medical Sciences

Country

Iran (Islamic Republic of)

Phone

+98 71 1647 4298

Email address

nzahrasan@yahoo.com

Recruitment status

Recruitment complete

Funding source

Expected recruitment start date

2021-12-22, 1400/10/01

Expected recruitment end date

2022-03-21, 1401/01/01

Actual recruitment start date

empty

Actual recruitment end date

empty

Trial completion date

empty

Scientific title

Comparison of therapeutic effects of Iranian surfactant (Beraksurf) with Curosurf in premature infants with respiratory distress admitted to the neonatal intensive care unit of Hafez and Namazi hospitals in Shiraz in 1400

Public title

Evaluation of the effect of Beraksurf and Curosurf in patients with respiratory distress

Purpose

Treatment

Inclusion/Exclusion criteria

Inclusion criteria:

Gestational age < 37 weeks Radiologic and clinical diagnosis during first 6 hours, Need to Fio₂>30% for keeping O₂ saturation 92-95% that measured by pulse oximetry

Exclusion criteria:

Patients with congenital disease and anomalies
Receiving two types of surfactant due to lack or shortage of the drug
Patients need operation
Neonates with congenital heart or lung disease or abdominal pathology

Age

No age limit

Gender

Both

Phase

3

Groups that have been masked

- Participant

Sample size

Target sample size: **100**

Randomization (investigator's opinion)

Randomized

Randomization description

En In this study, we will use the limited randomization method of block randomization, which is used to balance the number of participants in each study group. The size of the blocks is equal, and we will have 50 participants in each group. For block randomization, the size of the blocks is considered to be five. According to the sample size, 20 blocks will be selected based on a table of random numbers. The individuals are assigned to groups based on the position of the blocks. Random allocation concealment will be done using randomly sealed opaque envelopes. The random allocation sequence was computer-generated (Kendall and Smith's Random Numbers Table) by a statistician who was not a part of the research team. A random number table is a series of digits (0 to 9) arranged randomly in rows and columns, as demonstrated in the small sample below. The table usually contains 5-digit numbers, arranged in rows and columns, for ease of reading. The random allocation sequence was concealed in sealed opaque envelopes until the participants were assigned into two groups
participants were assigned into two groups

Blinding (investigator's opinion)

Single blinded

Blinding description

The blinding method in this study will be single-blind. The single-blind is used to reduce bias related to the

intervention and evaluate the consequences. In this study, samples of the research are blinded (parents know about the study drugs, but they will not be informed about grouping).

Placebo

Not used

Assignment

Parallel

Other design features

Secondary Ids

empty

Ethics committees

1

Ethics committee

Name of ethics committee

Ethics committee of Shiraz University of Medical Sciences

Street address

Zand street, Shiraz University of Medical Sciences, Shiraz

City

Shiraz

Province

Fars

Postal code

7134814336

Approval date

2021-10-30, 1400/08/08

Ethics committee reference number

IR.SUMS.REC.1400.569

Health conditions studied

1

Description of health condition studied

respiratory distress syndrome

ICD-10 code

P22.0

ICD-10 code description

Respiratory distress syndrome of newborn

Primary outcomes

1

Description

treatment of respiratory distress syndrome

Timepoint

evaluate respiratory condition of neonates at birth and 2, 6,12,18,24,36,48 and 72 hour after birth

Method of measurement

Beraksurf case report form

Secondary outcomes

empty

Intervention groups

1

Description

Intervention group 1: In this group, 50 neonates with RDS diagnosis will receive intratracheal Beraksurf (produced by Tekzima, Iran) at a dose of 2.5 cc/ kg (200 mg/kg) every 6-12 hours until the Fio2 is less than 30%. For subsequent doses, 100 mg/kg will be given up to three doses every 6 hours if needed.

Category

Treatment - Drugs

2

Description

Intervention group 2: In this group, 50 neonates with RDS diagnosis will receive intratracheal Curosurf (produced by chiesi, Italy) at a dose of 4 cc/kg (200 mg/kg) every 6-12 hours until the Fio2 is less than 30%. For subsequent doses, 100 mg/kg will be given up to three doses every 6 hours if needed.

Category

Treatment - Drugs

Recruitment centers

1

Recruitment center

Name of recruitment center

Nemazee hospital

Full name of responsible person

Khadijeh Sadat Najib

Street address

Nemazee square, Shiraz , Iran

City

Shiraz

Province

Fars

Postal code

71936133111

Phone

+98 71 3647 4298

Email

nzahrasan@yahoo.com

2

Recruitment center

Name of recruitment center

Hafez hospital

Full name of responsible person

Khadijeh Sadat Najib

Street address

Hafez hospital, Chamran Blvd, Shiraz, Iran

City

Shiraz

Province

Fars

Postal code

7194634786

Phone

+98 71 3647 9531

Email

Hafez@sums.ac.ir

Web page address

Sponsors / Funding sources

1

Sponsor

Name of organization / entity

Shiraz University of Medical Sciences

Full name of responsible person

Dr. Mahtab Memarpour

Street address

Shiraz University of Medical Sciences, Zand steert, Shiraz, Iran

City

Shiraz

Province

Fars

Postal code

7134814336

Phone

+98 71 3230 5417

Email

info@sums.ac.ir

Grant name

Grant code / Reference number

Is the source of funding the same sponsor organization/entity?

Yes

Title of funding source

Shiraz University of Medical Sciences

Proportion provided by this source

100

Public or private sector

Public

Domestic or foreign origin

Domestic

Category of foreign source of funding

empty

Country of origin

Type of organization providing the funding

Academic

Person responsible for general inquiries

Contact

Name of organization / entity

Shiraz University of Medical Sciences

Full name of responsible person

Khadijeh Sadat Najib

Position

Associate Professor

Latest degree

Subspecialist

Other areas of specialty/work

Neonatal

Street address

Nemazee hospital, Nemazee square, Shiraz, Iran

City

Shiraz

Province

Fars

Postal code

7193613311

Phone

+98 71 1647 4298

Fax

+98 71 1647 4298

Email

nzahrasan@yahoo.com

Person responsible for scientific inquiries

Contact

Name of organization / entity

Shiraz University of Medical Sciences

Full name of responsible person

Khadijeh Sadat Najib

Position

Associate Professor

Latest degree

Subspecialist

Other areas of specialty/work

Pediatrics

Street address

Nemazee hospital, Nemazee square, Shiraz, Iran

City

Shiraz

Province

Fars

Postal code

7193613311

Phone

+98 71 1647 4298

Fax

+98 71 1647 4298

Email

nzahrasan@yahoo.com

Person responsible for updating data

Contact

Name of organization / entity

Shiraz University of Medical Sciences

Full name of responsible person

Khadijeh Sadat Najib

Position

Associate professor

Latest degree

Subspecialist

Other areas of specialty/work

Pediatrics

Street address

Nemazee hospital, Nemazee square, Shiraz, Iran

City

Shiraz

Province

Fars

Postal code

7193613311

Phone

+98 71 1647 4298

Fax

+98 71 1647 4298

Email

nzahrasan@yahoo.com

Sharing plan

Deidentified Individual Participant Data Set (IPD)

Undecided - It is not yet known if there will be a plan to make this available

Study Protocol

Undecided - It is not yet known if there will be a plan to make this available

Statistical Analysis Plan

Undecided - It is not yet known if there will be a plan to make this available

Informed Consent Form

Undecided - It is not yet known if there will be a plan to make this available

Clinical Study Report

Undecided - It is not yet known if there will be a plan to make this available

Analytic Code

Undecided - It is not yet known if there will be a plan to make this available

Data Dictionary

Undecided - It is not yet known if there will be a plan to make this available